Tirzepatide shows biased agonism at the GIP receptor, preferentially activating the cAMP pathway while weakly stimulating other signaling pathways.
Biased toward cAMPTirzepatide preferentially activates the cAMP pathway at GIP receptors while weakly stimulating five other signaling pathways
What the researchers found
Tirzepatide showed biased agonism at the GIP receptor, meaning it preferentially activated the Gαs/cAMP pathway while having weaker effects on IP1 accumulation, AKT, ERK1/2, and CREB phosphorylation. This bias was consistent at both the wild-type (E354) and E354Q GIP receptor variants.
The natural GIP peptides GIP(1-42) and GIP(1-30)NH2 were generally equipotent across pathways, with one exception: GIP(1-30)NH2 was more potent than GIP(1-42) for CREB phosphorylation at the E354Q variant.
The E354Q variant is clinically relevant because it is associated with increased type 2 diabetes risk and lower body mass index. Understanding how drugs and natural peptides signal differently at this variant could help explain these clinical associations.
Why it matters
Tirzepatide is clinically more effective than pure GLP-1 drugs, but the reasons are not fully understood. This study reveals that tirzepatide's GIP receptor activity is biased toward cAMP, which could explain its unique pharmacological profile. The E354Q variant affects millions of people and may influence individual responses to tirzepatide.
The numbers in context
- GIP receptor variants studied: E354 (wild-type) and E354Q
- Signaling pathways: cAMP, IP1, AKT, ERK1/2, CREB phosphorylation
- Tirzepatide: biased toward cAMP at both variants
- GIP(1-42) and GIP(1-30)NH2: generally equipotent across pathways
- E354Q variant: associated with T2D risk and lower BMI
How the study worked
Researchers expressed wild-type (E354) and E354Q GIP receptors in Cos7 cells. They tested GIP(1-42), GIP(1-30)NH2, and tirzepatide across five signaling pathways: cAMP accumulation, IP1 accumulation, AKT phosphorylation, ERK1/2 phosphorylation, and CREB phosphorylation. Dose-response curves were generated for each drug at each receptor variant.
Who was studied
In vitro study using Cos7 cells expressing wild-type or E354Q GIP receptors
What this study cannot tell us
This was done in Cos7 cells (monkey kidney cells) that do not naturally express GIP receptors. Overexpression systems may not replicate native receptor signaling. The study used only three agonists. In vivo, tirzepatide acts on both GIP and GLP-1 receptors simultaneously, and this study only looked at GIP receptor signaling in isolation. The clinical significance of the signaling bias is inferred, not directly tested.
How to read the evidence
Rated moderate: well-designed in vitro receptor signaling study using multiple pathways and receptor variants, but conducted in overexpression systems.
When this study was published
Published in 2024. Part of the growing effort to understand why tirzepatide's dual mechanism outperforms single-target drugs.
The bigger picture
Tirzepatide is more effective than pure GLP-1 drugs, but the reasons are not fully understood. Its biased GIP receptor signaling may produce different downstream effects than natural GIP, potentially contributing to its superior metabolic benefits.
Questions still open
- Does biased cAMP signaling explain tirzepatide's clinical advantages?
- Could designing drugs with specific signaling biases improve future metabolic therapies?
Common questions
What is biased agonism?
Why does tirzepatide work better than semaglutide?
Read the original research
Tirzepatide, GIP(1-42) and GIP(1-30) display unique signaling profiles at two common GIP receptor variants, E354 and Q354.
Frontiers in pharmacology, 15, 1463313
Citation
Rees, Tayla A; Buttle, Benjamin J; Tasma, Zoe; Yang, Sung-Hyun; Harris, Paul W R; Walker, Christopher S. (2024). Tirzepatide, GIP(1-42) and GIP(1-30) display unique signaling profiles at two common GIP receptor variants, E354 and Q354.. Frontiers in pharmacology, 15, 1463313. https://doi.org/10.3389/fphar.2024.1463313